J. Böttcher

发表

Structure–kinetic relationship study of CDK8/CycC specific compounds

R. Huber, L. Neumann, E. Schneider, 2013, Proceedings of the National Academy of Sciences.

An old target revisited: two new privileged skeletons and an unexpected binding mode for HIV-protease inhibitors.

Gerhard Klebe, Nils Griebenow, Jark Böttcher, 2005, Angewandte Chemie.

Unexpected Novel Binding Mode of Pyrrolidine‐Based Aspartyl Protease Inhibitors: Design, Synthesis and Crystal Structure in Complex with HIV Protease

G. Klebe, A. Heine, G. Müller, 2006, ChemMedChem.

Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.

G. Klebe, A. Heine, A. Blum, 2011, Journal of molecular biology.

Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.

Gerhard Klebe, Wibke E Diederich, Jark Böttcher, 2008, Journal of medicinal chemistry.

Targeting the Open‐Flap Conformation of HIV‐1 Protease with Pyrrolidine‐Based Inhibitors

G. Klebe, A. Heine, A. Blum, 2008, ChemMedChem.

Structure-based Development of Secondary Amines as Aspartic Protease Inhibitors

J. Böttcher, 2008 .

Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.

G. Klebe, A. Heine, A. Blum, 2008, Bioorganic & medicinal chemistry.

Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.

Gerhard Klebe, Wibke E Diederich, Jark Böttcher, 2008, Journal of molecular biology.

Getting a Grip on the Undrugged: Targeting β‐Catenin with Fragment‐Based Methods

Julian E. Fuchs, M. Pearson, D. Breitsprecher, 2020, ChemMedChem.

Drugging all RAS isoforms with one pocket.

G. Fischer, A. Bergner, J. Böttcher, 2020, Future medicinal chemistry.

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

P. Ettmayer, S. Carotta, M. Kerenyi, 2020, Molecular Cancer Therapeutics.

A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway

P. Nuciforo, Rachel Kroe-Barrett, J. Capdevila, 2021, Molecular Cancer Therapeutics.

Crystal Structure of the Werner’s Syndrome Helicase

Matthias Samwer, O. Gileadi, Simone Lieb, 2020, bioRxiv.

Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3

Julian E. Fuchs, O. Fedorov, C. Arrowsmith, 2019, Nature Chemical Biology.

HUWE 1 employs a giant substrate-binding ring to feed and regulate its HECT E 3 domain 1 2

O. A. Petrova, R. Kurzbauer, D. Haselbach, 2021 .

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

A. Waterson, D. Rudolph, M. Gmachl, 2022, Journal of medicinal chemistry.

Synthesis, characterisation and natural abundance Os-187 NMR spectroscopy of hydride bridged triosmium clusters with chiral diphosphine ligands

J. Steed, A. Aliev, J. Böttcher, 2006 .

Donated chemical probes for open science

Anton Simeonov, Steve Hitchcock, Stefan Laufer, 2018, eLife.

The Potential of P1 Site Alterations in Peptidomimetic Protease Inhibitors as Suggested by Virtual Screening and Explored by the Use of CC‐Coupling Reagents

G. Klebe, C. Sotriffer, A. Evers, 2006, ChemMedChem.

The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder.

R. Huber, L. Neumann, E. Schneider, 2011, Journal of molecular biology.

Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody

M. Augustin, R. Ostendorp, J. Böttcher, 2016, mAbs.

Synthesis of 2,3,4,7-tetrahydro-1H-azepines as privileged ligand scaffolds for the design of aspartic protease inhibitors via a ring-closing metathesis approach

Christof Gerlach, J. Böttcher, S. Brass, 2006 .

Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology.

S. Steinbacher, H. Steuber, R. Kiefersauer, 2011, Methods in enzymology.

Inverse PI by NMR: Analysis of Ligand 1H-Chemical Shifts in the Protein-Bound State

Julian E. Fuchs, R. Konrat, J. Böttcher, 2021, bioRxiv.

Quinoline‐Based Derivatives of Pirinixic Acid as Dual PPAR α/γ Agonists

M. Schubert-Zsilavecz, J. Böttcher, O. Rau, 2007 .

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

P. Ettmayer, N. Kraut, M. Gmachl, 2021, Journal of medicinal chemistry.

HUWE1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domain

O. A. Petrova, R. Kurzbauer, D. Haselbach, 2021, Nature Chemical Biology.

Target 2035 – an update on private sector contributions

T. Willson, S. Knapp, U. Lessel, 2023, RSC medicinal chemistry.

Structure of the helicase core of Werner helicase, a key target in microsatellite instability cancers

Matthias Samwer, O. Gileadi, Simone Lieb, 2020, Life Science Alliance.

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

E. de Stanchina, Y. Pourfarjam, N. Kraut, 2023, Nature.